To assess the effectiveness of a local Unani formulation in patients with Eczema.

To evaluate the safety and efficacy of a Topical Unani formulation in the management of NÄ?r-fÄ?rsÄ« (Eczema) with standard control.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050788

Enrollment

Registered

2023-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L208- Other atopic dermatitis

Interventions

Intervention1: Topical Unani Formulation: Momatasone 0.1% Intervention2: Topical Unani Formulation: It is a classical unani formulation taken from Bayaz-e-Kabir. The formulation comprises of Murdarsun

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed patients of eczema. Mild to moderate case of eczema. Patients who have agreed to sign the informed consent, follow the protocol and willing to participate the clinical trial voluntarily.

Exclusion criteria

Exclusion criteria: Patients below 18 and above 30 years are excluded. Local wound and infection. Patients with systemic diseases like cardiovascular, renal and hepatic dysfunctions. Severe case of Dermatitis. Pregnancy and Lactation.

Design outcomes

Primary

Measure	Time frame
Patients Oriented Eczema Measure (POEM) questionnaire to be assessed at baseline and 41st day Eczema Area Severity Index (EASI) score at baseline and 41st day Photographs of lesions at baseline and 41st day.Timepoint: 40 days	—

Secondary

Measure	Time frame
Itching Presence of dry skin Erythematous patches Excoriated lesions.Timepoint: 40 days	—

Countries

India

Contacts

Public ContactDr zaffar Hussain

Regional research institute of unani medicine

hussainzaffar6@gmail.com7006021996

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026